苏州赛分科技股份有限公司 内部审计管理制度 第一章 总则 第一条 为了规范苏州赛分科技股份有限公司（以下简称"公司"）的内部审计 工作，提高审计工作质量，实现公司内部审计经常化、制度化，发挥内部审计工作 在促进企业经济管理、提高经济效益中的作用，根据《中华人民共和国审计法》、《企 业内部控制基本规范》、《上海证券交易所科创板股票上市规则》等有关法律、法规、 规范性文件的规定，结合公司实际情况，制定本制度。 第二条 本制度规定了公司内部审计机构及内部审计人员的职责与权限、内部审 计对象和时限、内部审计工作的内容及工作程序、审计业务文书、审计档案管理等 规范，是公司开展内部审计管理工作的标准。 本制度所称内部审计，是指由公司内部机构或人员，对其内部控制和风险管理 的有效性、财务信息的真实性和公允性以及经营活动的效率和效果等开展的一种评 价活动。 本制度所称内部控制，是指公司董事会、审计委员会、高级管理人员及其他有 关人员为实现下列目标而提供合理保证的过程：遵守国家法律、法规、规章及其他 相关规定；提高公司经营的效率和效果；保障公司资产的安全；确保公司信息披露 的真实、准确、及时、完整和公平。 第三条 本制度适用于 ...

第一条 为规范苏州赛分科技股份有限公司（以下简称"公司"）信息披 露暂缓与豁免行为，保障公司依法合规履行信息披露义务，维护公司和投资者 的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司信息披露暂缓与豁免管理规定》以及证券交易所相关股票上市规则、自 律监管指引等有关法律、法规等有关规定，制定本制度。 第二条 公司按照证券交易所股票上市规则及其他相关业务规则的规定， 暂缓、豁免披露临时报告，在定期报告、临时报告中豁免披露中国证券监督管 理委员会（以下简称"中国证监会"）和证券交易所规定或者要求披露的内容， 适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平 地披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不 得实施内幕交易、操纵市场等违法行为。 第四条 公司和其他信息披露义务人应当审慎确定信息披露暂缓、豁免事 项，履行内部审核程序后实施。暂缓、豁免事项的范围原则上应当与公司股票 首次在证券交易所上市时保持一致，在上市后拟增加暂缓、豁免披露事项的， 应当有确实充分的证据。 苏州赛分科技股份有限公司 信息披露暂缓与豁免管理制度 第一章总则 第二 ...

苏州赛分科技股份有限公司2025 年半年度报告 公司代码：688758 公司简称：赛分科技 苏州赛分科技股份有限公司 2025 年半年度报告 1 / 197 苏州赛分科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 □适用 √不适用 八、 前瞻性陈述的风险声明 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本半年度报告 中详细描述可能存在的风险，敬请查阅本报告"第三节管理层讨论与分析"之"四、风险因素" 中的内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人黄学英、主管会计工作负责人卞庆莲及会计机构负责人（会计主管人员）王希 雅声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经公司第二届董事会2025年第四次会议审议，公司2025年半年度拟以实施权益分派股权登记 日登记的总股本为基数分配利润，本次利润分配方案如下 ...

人民财讯8月18日电，赛分科技(688758)8月18日晚间披露2025年半年报，公司上半年实现营业收入1.83 亿元，同比增长19.76%；归母净利润为5365.92万元，同比增长40.91%。基本每股收益0.1315元。公司 拟向全体股东每10股派发现金红利0.26元(含税)。报告期内，公司归母净利润的快速增长主要得益于公 司营业收入的增长，以及随着业务规模扩大，固定成本得到有效摊薄，带动整体净利润率显著提升。 ...

Core Viewpoint - The company reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong growth driven by its focus on specific market segments and customer relationships [1] Financial Performance - The company achieved operating revenue of 183 million yuan, representing a year-on-year growth of 19.76% [1] - The net profit attributable to shareholders reached 53.66 million yuan, marking a year-on-year increase of 40.91% [1] - The net profit after deducting non-recurring gains and losses was 46.50 million yuan, reflecting a year-on-year growth of 22.08% [1] - Basic earnings per share were reported at 0.1315 yuan [1] Dividend Distribution - The company plans to distribute a cash dividend of 0.026 yuan per share (tax included) to all shareholders [1] Business Strategy - The revenue growth is attributed to the company's focus on the fields of analytical chromatography and industrial purification, along with continuous market expansion efforts [1] - The company leveraged product performance and independent research and development advantages to acquire new customer projects and promote repeat purchases from existing customers [1]

赛分科技公告，2025年上半年营业收入1.83亿元，同比增长19.76%。净利润5365.92万元，同比增长 40.91%。公司拟向全体股东每股派发现金红利人民币0.026元（含税），合计拟派发现金红利人民币 1082.81万元（含税），占2025年半年度归属于上市公司股东净利润的20.18%。 ...

Company Overview - Sai Fen Technology closed at 18.62 yuan on August 12, down 1.74% from the previous trading day [1] - The opening price was 18.95 yuan, with a high of 18.95 yuan and a low of 18.50 yuan, and the trading volume reached 26,462 hands, amounting to 0.49 billion yuan [1] Business Focus - The company specializes in the research, production, and sales of chemical raw materials and intermediates, primarily serving the pharmaceutical, pesticide, and dye industries [1] - As a pharmaceutical enterprise in Jiangsu, the company is part of the chemical raw materials sector and holds the qualification of a specialized and innovative enterprise [1] Industry Insights - According to the Jiangsu Provincial Drug Administration, 14 innovative drugs were approved for market in Jiangsu from January to July this year, surpassing the total for the entire year of 2024 [1] - These innovative drugs cover multiple therapeutic areas, including oncology, spondylitis, and influenza, featuring several landmark "first" products [1] - Jiangsu's biopharmaceutical industry accounts for approximately 15% of the national market, ranking first in the country [1] Market Activity - On August 12, the net outflow of main funds for Sai Fen Technology was 1.8355 million yuan, representing 0.23% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 3.6028 million yuan, accounting for 0.46% of the circulating market value [1]

Core Viewpoint - The article discusses the advantages of domestic substitution in the biopharmaceutical supply chain, emphasizing stability, safety, and cost-effectiveness as key drivers for companies to adopt domestic products over imports [3][4]. Group 1: Domestic Substitution Advantages - The stability and safety of the supply chain are crucial for biopharmaceutical companies, especially during disruptions that could lead to production halts. Domestic sourcing mitigates risks associated with reliance on imported critical materials [3]. - Cost advantages are significant, with domestic chromatography media offering substantial price reductions compared to imported counterparts. This cost-effectiveness is enhanced when considering the overall supply chain, as companies often switch multiple related consumables to domestic options [3]. - Domestic suppliers provide localized technical support, collaborating closely with clients to optimize processes and improve product quality, which fosters a competitive environment focused on comprehensive technical solutions [3]. Group 2: Industry Trends - The trend towards domestic substitution in chromatography media is largely irreversible, with most companies moving from imported to domestic products, and only a few instances of switching between domestic brands [4]. - Large pharmaceutical companies adopt a mixed procurement strategy for chromatography media, balancing between single and multiple suppliers based on their process needs and risk management considerations [5]. - The primary business of the company, Saifen Technology (688758), focuses on the research, development, and production of liquid chromatography materials for drug analysis and purification, positioning itself as a high-tech enterprise with global sales capabilities [5].

Core Viewpoint - The company, Saifen Technology (688758), is focusing on the domestic substitution of chromatography media in the biopharmaceutical supply chain, emphasizing stability, safety, and cost advantages over imported products [2][3]. Group 1: Industry Insights - The domestic substitution strategy is driven by the need for supply chain stability and safety, especially highlighted during periods of disruption when reliance on imported materials posed risks to production continuity [2]. - Cost advantages of domestic products, such as affinity chromatography and ion exchange chromatography media, significantly reduce expenses compared to imported alternatives, enhancing overall cost-effectiveness for clients [2]. - Local suppliers are improving their technical support and collaboration with clients, leading to better process development and optimization, which enhances product purity and yield [2]. Group 2: Company Performance - Saifen Technology reported a main revenue of 83.59 million yuan for Q1 2025, an increase of 8.87% year-on-year; however, net profit attributable to shareholders decreased by 1.02% to 23.71 million yuan [4]. - The company's debt ratio stands at 5.2%, with a gross profit margin of 74.14% [4]. - Recent institutional ratings indicate a positive outlook, with two firms issuing "buy" ratings and a target price of 17.85 yuan [5][6]. Group 3: Market Trends - The trend in the industry shows a low likelihood of reverting to imported chromatography media once domestic alternatives are adopted, indicating a long-term shift towards local products [3]. - Large pharmaceutical companies are diversifying their supplier strategies, balancing between single and multiple suppliers based on their process needs and risk management [4]. Group 4: Financial Forecasts - Financial forecasts predict net profits of 102 million yuan for 2025, increasing to 126 million yuan in 2026, and 148 million yuan in 2027 [6]. - Recent financing data shows a net inflow of 31.98 million yuan over the past three months, indicating increased investor interest [6].

Core Points - In the first seven months of 2025, a total of 59 new companies were listed on the Shanghai Stock Exchange, Shenzhen Stock Exchange, and Beijing Stock Exchange, raising a total of 59.116 billion yuan [1] - Among these, the Sci-Tech Innovation Board saw 8 companies listed, collectively raising 8.117 billion yuan [1] - Seven companies opted for the first set of listing standards, which require a minimum expected market value of 1 billion yuan and specific profit and revenue criteria [1] Company Listings - Yitang Co., Ltd. (688729.SH) was listed on July 8, 2025, raising 2.49748 billion yuan with underwriting fees of 92.2118 million yuan, following the fourth listing standard [2] - Yingstone Innovation (688775.SH) was listed on June 11, 2025, raising 1.93807 billion yuan with underwriting fees of 158.3475 million yuan, adhering to the first listing standard [2] - Hanbang Technology (688755.SH) was listed on May 16, 2025, raising 500.94 million yuan with underwriting fees of 37.2891 million yuan, also following the first listing standard [2] - Other companies listed under the first standard include Shengke Nano (688757.SH), Haibosichuang (688411.SH), Xingfu Electronics (688545.SH), Sikan Technology (688583.SH), and Saifen Technology (688758.SH), with varying amounts raised and underwriting fees [2]